Real-world Canadian Retrospective Study Evaluating Longitudinal Semaglutide Use on Cardio-Kidney-Metabolic Outcomes

Study acronym: SEMA-CKM
StatusCompleted
PhaseNot specified
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Lead sponsor: LMC Diabetes & Endocrinology Ltd. to LMC Diabetes & Endocrinology Ltd. Show 7 more changesShow less
    • Completed without a posted recruiting period
    • Final enrollment: 3392 participants (planned 400)
    • Primary completion date changed from estimate of Apr 2026 to Sep 28, 2026
    • Study sites: 0 to 1
    • Start date changed from estimate of Mar 2026 to Feb 20, 2026
    • Eligibility criteria expanded, about 21 words
    • Secondary endpoints: details revised at 19 of 68 entries
  2. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
The goal of this study is to better understand the real-world effectiveness of semaglutide use on cardio-kidney-metabolic outcomes among adults with T2D and adults with obesity (without diabetes mellitus). This is a retrospective longitudinal analysis using the LMC Diabetes Registry. The primary outcome of the study is to evaluate the change in HbA1c between baseline to 3 years of follow-up among adults with T2D who initiated semaglutide compared to adults with T2D who initiated other AHAs, including sulfonylurea, dipeptidyl peptidase-4 inhibitors, and sodium-glucose cotransporter-2 inhibitors.
Trial Details
NCT Number NCT07424430
Lead Sponsor LMC Diabetes & Endocrinology Ltd.
Conditions
(from sponsor)		 Diabetes (DM), Type 2 Diabetes, Obesity (Disorder)
Related terms Diabetes Mellitus, Diabetes Mellitus, Type 2, Obesity
Enrollment 3,392 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov